Short Interest in MDxHealth SA (NASDAQ:MDXH) Expands By 140.1%

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 38,900 shares, an increase of 140.1% from the November 15th total of 16,200 shares. Based on an average daily trading volume, of 141,500 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s shares are sold short.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently modified their holdings of MDXH. Perkins Capital Management Inc. lifted its stake in shares of MDxHealth by 70.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after purchasing an additional 309,500 shares during the last quarter. MVM Partners LLC grew its position in MDxHealth by 3.3% during the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after buying an additional 150,000 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of MDxHealth by 15.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares in the last quarter. Finally, Maven Securities LTD bought a new stake in MDxHealth in the 3rd quarter valued at $208,000.

Analyst Ratings Changes

MDXH has been the subject of several research analyst reports. Lake Street Capital began coverage on shares of MDxHealth in a research report on Thursday, October 31st. They issued a “buy” rating and a $7.00 price target for the company. Piper Sandler reduced their target price on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, November 7th.

MDxHealth Stock Up 1.7 %

Shares of MDXH stock traded up $0.04 during trading on Friday, hitting $2.40. 25,751 shares of the company were exchanged, compared to its average volume of 77,338. The business’s 50-day simple moving average is $1.99 and its 200 day simple moving average is $2.44. MDxHealth has a twelve month low of $1.55 and a twelve month high of $4.64. The firm has a market capitalization of $3.74 million, a price-to-earnings ratio of -1.58 and a beta of 1.42. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.